Daily Archives: September 14, 2021

They say you dont truly understand something until youve experienced it yourself, and thats certainly been true for me. After spending nearly a decade writing about beauty, I have only recently come to know how challenging it can be to find beauty products that wont irritate sensitive skin.

Earlier this summer, I found myself facing eczema for the first time in my life. I suddenly had raised, rough patches on my cheeks and eyelids, and these never-ending flaky patches around my forehead that my dermatologist recently diagnosed as seborrheic dermatitis. Fun.

I went from using a varied regimen of serums and creams to a very pared down routine thats so bland it blends into my white medicine cabinet. The same goes for my hair products and makeup, which is what were going to dive into now.

In the throes of another flare up, I had the chance to speak with Allan Avendao, who is a celebrity makeup artist to Addison Rae, Vanessa Hudgens and Sarah Hyland among others. Though Ive long admired his work on Instagram, I was especially excited to talk to Allan because he is also intimately familiar with the difficulties of navigating the beauty aisles with a skin condition; hes had plaque psoriasis, which is a chronic autoimmune disease that appears on the surface of the skin as raised, red, itchy patches, since he was a kid.

Here are some of the key takeaways I learned from our convo.

One of the top offenders when it comes to causing irritation is fragrance. (A few other culprits to watch for are parabens, formaldehydes and alcohol.) Fragrance is found in many, if not most, beauty products, so youll need to look carefully at the ingredient lists to make sure its not hiding there.

On the flip side, some ingredients you want in your products are hyaluronic acid, glycerin and ceramides. These hydrating ingredients help draw in moisture and lock it in, which is crucial because dehydrated skin is more prone to inflammation.

So, before you proceed with any makeup, always make sure to gently cleanse (never scrub) your face and follow up with a layer of moisturizer to prep your skin.

Finally, when youre dealing with sensitive skin or skin conditions like eczema or psoriasis, its always good practice to patch test any new products before you commit to a full face.

Whether its a new foundation or a blush, apply a small amount of it to the inside of your wrist and see if your skin reacts to the formula. If it causes any sort of irritation to your wrist, its likely going to do the same to your face. If theres no reaction, you can proceed.

OK, so this isnt technically makeup, but sunscreen is a must, and this derm-approved formula also has enough tint in it to even out the reddest tones on your skin. Plus, its very moisturizing and leaves a subtle glow behind. Most importantly, it doesnt trigger a reaction thanks to its fragrance-free and zinc oxide-based formula. (Note: Physical sunscreens tend to work better for those of us with sensitive skin.)

Buy it ($39)

On days where I want just a little more coveragebe it under my eyes or over any splotchesIll tap a small amount of this creamy stick wherever its needed. The formula is easy to blend and quickly blurs out any areas of discoloration to create a more even-looking finish. Currently its available in 20 shades and is formulated to EU standards, which are among the strictest, and eliminates any ingredients that might trigger inflammation such as artificial fragrance.

Buy it ($38)

With a tagline that states: Designed for sensitive skin, made for all, I had high hopes that this would be safe for me to use. Thankfully, it passed the patch test and Ive been able to enjoy this buttery blush without any issues. The six shades can be sheered out or built up to your desired level of color and the results are always natural looking.

Buy it ($20)

This highlighter has won many awards (and picked up many celebrity fans) over the years thanks to the soft, never sparkly glow it leaves on your skin. With a streamlined ingredient list thats mostly made up of castor seed and coconut oil, you can put it on your skin without having to worry about aggravating it.

Buy it ($38)

Eyelid eczema makes it difficult to wear most eyeshadows, which is why I was ecstatic when this palette passed my patch test. As it turns out, many of Tartes products are mineral-based, which is often recommended for people with sensitive skin. Each of the 12 shades in the palette are also infused with Amazonian clay to give them a creamier consistency and better color payoff. From a warm taupe to a chestnut brown (and multiple shades of bronze, tan and peach in-between), you can easily create different looks to fit any occasion.

Buy it ($39)

And for the finishing touch, Ive been wearing this buttery lip gloss from Minori. There are four, universally flattering shades to choose from, but I find myself wearing Juneberry the most, which is a cool pink with a subtle shimmer. The gloss itself is velvety and hydrating on your lips and leaves nary a flake behind.

Buy it ($22)

RELATED: The 25 Best Lip Glosses to Keep Your Lips Plump, But Not Sticky

Read the original:
The Best Makeup for Sensitive Skin, According to a Beauty Editor with Eczema - PureWow

WEDNESDAY, Sept. 8, 2021 (HealthDay News) -- Eczema doesn't just irritate kids' skin. The often disfiguring condition may also be tied to depression, anxiety and sleep difficulties, new research warns.

A study of more than 11,000 British children and teens found that those with severe eczema were twice as likely to become clinically depressed as eczema-free kids.

"Eczema is an itchy red skin disease," said study author Dr. Katrina Abuabara, an associate professor of dermatology at the University of California, San Francisco.

But it's complex.

"The disease course and severity can be quite variable," explained Abuabara. "It often presents in early childhood, but can occur at any age. It tends to be episodic, flaring up, then remitting, but these cycles can be chronic over years.

"For many children, the disease seems to improve by their teen years, but we've found that some continue to have episodic disease into adulthood," she added.

Risk goes up among those with a family history of the disease or related conditions like asthma and allergies. And the condition "is quite common, affecting up to 20% of kids and 10% of adults," Abuabara noted.

Among the children she and her colleagues started tracking in 1991, the annual prevalence of eczema -- also known as atopic dermatitis -- ranged from 14% to 19% between the ages of 3 and 18.

Roughly 22% to 40% developed a moderate or severe form of the disease; the rest of the cases were mild.

In addition to being linked to a doubling of depression risk, severe eczema also doubled the risk for the kind of depressive and/or anxiety-linked behaviors that typically indicate underlying emotional and psychological difficulties. Severe cases also drove up the odds for sleep troubles.

The depressed children were more likely to be female, and from a higher social class, the authors found.

Mild and moderate eczema were not linked to a higher risk for childhood depression, the team stressed. But among children as young as 4, even less serious cases of eczema were associated with a 29% to 84% spike in the risk for internalizing behaviors.

That's concerning, Abuabara and her colleagues noted, because children who struggle with depression and/or brewing emotional turmoil may face a higher risk for depression, anxiety and poor overall health as adults.

"Many parents of children with eczema will tell you it can be a deceptively devastating disease," Abuabara said.

"Eczema has long been known to cause sleep disturbances which impact the whole family," she added, "and certainly can take a toll on emotional well-being. Increasingly, studies are revealing that some types of eczema are more than 'skin deep', and can impact overall health in a variety of ways."

In general, "skin disease is well known to affect patients' quality of life and cause depression," agreed Dr. Robert Kirsner, chairman of the department of dermatology and cutaneous surgery at the University of Miami Miller School of Medicine.

Children are often thought to be relatively resilient in that respect, said Kirsner, who was not part of the study team.

But "understandably, severe eczema, even in children, can cause depression and associated internalizing symptoms such as low self-esteem, fear and worrying," he said.

Of note is the finding that even "less severely affected patients apparently are emotionally affected by disease, and may internalize their feelings and manifest symptoms," Kirsner said.

This suggests "more aggressive, expert treatment for even mild eczema might improve the lives of children, and has potential for longer term mental health benefits," he added.

What can parents do?

Abuabara said they should strive to get the best care possible, not only for eczema itself but for the emotional hardship it may trigger.

"If you have a child with eczema that you're concerned about, it is important to talk to their doctor about optimizing their eczema treatment and to ask about behavioral screening and support through their clinic and/or school," Abuabara said.

The findings appear in the Sept. 1 online edition of JAMA Dermatology.

More information

There's more on eczema at the National Eczema Association.

SOURCES: Katrina Abuabara, MD, MSCE, associate professor, dermatology, University of California, San Francisco, and associate adjunct professor of epidemiology, University of California, Berkeley School of Public Health; Robert Kirsner, MD, PhD, chairman and professor, department of dermatology and cutaneous surgery, University of Miami Miller School of Medicine, and director, University of Miami Hospital and Clinics Wound Center; JAMA Dermatology, Sept. 1, 2021, online

Continue reading here:
Eczema Can Take Toll on Child's Mental Health - HealthDay News

Pfizer (NYSE:PFE) recently reported positive results for its experimental drug abrocitinib in a late-stage study targeting eczema, an inflammatory skin disease also known as atopic dermatitis. The study featured a head-to-head comparison between Pfizer's drug and Dupixent, which is marketed by Sanofi (NASDAQ:SNY) and Regeneron (NASDAQ:REGN).

Could Pfizer beat Sanofi and Regeneron in the eczema market? That's the topic of discussion inthis Motley Fool Live video recorded on Sept. 1, 2021, with Motley Fool contributors Keith Speights and Brian Orelli.

Keith Speights: Let's turn to some non-COVID news for some big players in the COVID-19 market. Pfizer recently reported its top-line results from a phase 3 study of abrocitinib. This study was a head-to-head comparison between abrocitinib and Sanofi'sand Regeneron'sDupixent in treating eczema (or atopic dermatitis).

Brian, what do you think about Pfizer's news here? Does the company have a chance of even beating Sanofi and Regeneron in the eczema market?

Brian Orelli: This was a top-line result, all we know is that the trial was successful, we don't actually have any data.

The study measured the percent of patients who had a four-point improvement on a scale that measures itching. Then they also measured the percent of patients who had a 90 percent clearance of their eczema.

Abrocitinib beat Dupixent on both of those endpoints. We just don't know by how much and obviously, the delta there and how many more people were helped. This obviously is going to be very important, but Pfizer's saving that data for a medical meeting or for a publication. Well, efficacy is certainly important, so is safety.

Abrocitinib is in the JAK class, which is has been marred with safety issues since the post-marketing study of Pfizer's Xeljanz showed that the drug had a higher rate of cardiovascular issues and also higher rates of cancer. There were two deaths in this study that was just published.

One was COVID-19 related, so probably not that big of a deal. But the other one was an intracranial hemorrhage and cardiorespiratory arrest. That's clearly cardiovascular. The investigators characterize it as unrelated to the drug. But I think it's just going to add fuel to this fire with the safety issues with JAK inhibitors.

Ever since, abrocitinib is under FDA review for eczema. The FDA has put off a decision on the drug. The PDUFA date has already passed. The goal that the FDA sets for itself to make a decision and it let that PDUFA date pass, because it's still reviewing the Xeljanz data. So it's going to make it a decision on the Xeljanz data and then make a decision on abrocitinib and a few other JAK inhibitors that also are under review that should have already had a decision for. We'll have to wait and see what warning abrocitinib gets before we can really know how well it can compete against Dupixent.

This article represents the opinion of the writer, who may disagree with the official recommendation position of a Motley Fool premium advisory service. Were motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Link:
Can Pfizer Beat Sanofi and Regeneron in the Eczema Market? - Motley Fool

Over 70 percent of the immune system is located within the gut, so eliminating any possible food allergies from the diet could help to reduce the high levels of circulating IgE.

The most common food allergies in patients with eczema are milk, egg, and peanuts, according to Claire.

She said: Eliminating these allergens from the diet for at least two weeks, before slowly reintroducing them one by one should provide clues to which ones, if any, are causing symptoms or flare-ups.

If eliminating any food groups from the diet, especially with infants and young children, I would strongly recommend seeking the advice of a local registered Nutritional Therapist as you do this, to reduce the likelihood of nutritional deficiencies.

If the infant is still being breastfed, the mother may wish to try an elimination diet whilst looking for corresponding symptoms in the infants skin condition.

Buy great deals forVitamins, Minerals & Supplements on Amazon here

Read more from the original source:
Best supplements for eczema - 4 tablets to take to beat the skin condition - Express

Atopic dermatitis (eczema) is a skin condition that leads to redness and itchiness. It's common in children but can occur at any age.

Atopic dermatitis usually develops in early childhood

Atopic Dermatitis (AD) is the most common form of eczema. It is an inflammatory skin condition, a chronic long-lasting disease characterized by dry, itchy skin that oozes or can weep clear fluid when scratched and flares up periodically. The exact cause is unknown but personal history of allergies, allergies, family history of eczema, asthma, or hay fever, are major risk factors for atopic dermatitis.

Common symptoms on the basis which AD is diagnosed, especially who are suffering from moderate to severe AD are rashes that can potentially cover much of the body and can include rough, leathery, or scaly patches, intense persistent itching, skin wounds and dryness, pain, cracking, redness, or darkness, crusting and oozing.

Burden around Atopic Dermatitis

AD affects at least 2 % to 3% of adults and 25% of children. It is also stated that about 10% -15 % of Indian population, has some form of atopy and manifestation of AD since the 1st year of their life. The burden of atopic dermatitis (AD) is high. Moderate to severe childhood AD shows greater family impact than type-1 diabetes.

This chronic condition has significant disease burden and higher prevalence of atopic and psychological comorbidities, impaired health - related quality of life, anxiety, and depression. The burden is even higher among patients with inadequately controlled AD. About 90% of AD patients experience daily itch and two- thirds have sleep disturbance. Comorbidities included other atopic disorders, infections, obesity, growth disturbance, deficit hyperactivity disorder and mental health disease, speech disorder, headaches, organ specific autoimmunity, and anemia. Persistent disease is particularly costly and appears to correlate with later onset, preexisting duration, and severity. However, persistent, early onset particularly herald possible future food and respiratory allergy, with their attendant burdens (and more severe) disease appears to.

Need for awareness and better treatment

Experts have observed that patients suffering from AD have a 44% more likelihood of mental health issuesas compared to those without atopic dermatitis. Patients often suffer from disturbed sleep, low work productivity, increased activity impairment and susceptibility to suicidal behavior. Which emphasizes the fact that atopic dermatitis aggravates and impacts not just physical and mental health, but it also leads to development of other disorders.

People living with AD are also predisposed to bacterial, viral, and fungal skin infections. Majority of the adults try treating AD with OTC products, until it reaches a severe level, which cannot be ignored. This is due to lack of awareness on the disease. However, this can be changed by acting when you notice early signs and common symptoms of atopic dermatitis and visit the dermatologist on priority.

Early diagnosis and providing access to optimal care and timely treatment for patients living with AD can help them live a better quality of life. By and large 80-85% AD hits children between 2-15 years of age when, physical and mental development, studies, career development are the priority. Hence AD has a far-reaching consequence on the future psycho-social growth of a child suffering from AD.

(Dr. Sandipan Dhar is aProfessor & Head of Paediatric Dermatology atInstitute of Child Health, Kolkata)

Disclaimer: The opinions expressed within this article are the personal opinions of the author. NDTV is not responsible for the accuracy, completeness, suitability, or validity of any information on this article. All information is provided on an as-is basis. The information, facts or opinions appearing in the article do not reflect the views of NDTV and NDTV does not assume any responsibility or liability for the same.

Link:
Atopic Dermatitis Day: Everything You Need To Know About This Skin Condition - Doctor NDTV

WILMINGTON, Del., September 13, 2021--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced that multiple abstracts highlighting data for ruxolitinib cream, an investigational topical JAK1/JAK2 inhibitor, in patients with vitiligo and atopic dermatitis (AD) will be presented at the upcoming European Academy of Dermatology and Venereology (EADV) 30th Anniversary Congress, held virtually from September 29-October 2, 2021.

The 24-week data from the Phase 3 TRuE-V program evaluating the safety and efficacy of ruxolitinib cream in adolescent and adult patients (age 12 years) with vitiligo will be presented as a late-breaking oral presentation. Incyte previously announced that both the TRuE-V1 and TRuE-V2 studies met the primary and key secondary endpoints.

"We look forward to sharing data demonstrating the potential of ruxolitinib cream as an effective treatment option for patients living with vitiligo with the dermatology community at this years EADV virtual congress," said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation & Autoimmunity, Incyte. "These data from the Phase 3 TRuE-V program underscore our commitment to bringing new therapies to patients with challenging skin diseases."

Key abstracts include:

Late-Breaking Oral Presentation

Vitiligo

Efficacy and Safety of Ruxolitinib Cream for the Treatment of Vitiligo: 24-Week Results From 2 Randomized, Double-Blind Phase 3 Studies (Abstract #D3T01.2A. Session: Late Breaking News. Saturday, October 2, 5:15-6:15 a.m. ET)

Oral Presentation

Atopic Dermatitis

Efficacy and Safety of Ruxolitinib Cream among Patients Aged 65 Years with Atopic Dermatitis: Pooled Results from Two Phase 3 Studies (Abstract #FC01.01. Session: Atopic dermatitis/Eczema. Thursday, September 30, 4:00-4:10 a.m. ET)

Poster Presentations

Atopic Dermatitis

Story continues

Efficacy of Ruxolitinib Cream for the Treatment of Atopic Dermatitis by Baseline Clinical Characteristics (encore) (Abstract #P0187. Session: Atopic dermatitis/Eczema)

Efficacy of Ruxolitinib Cream among Patients with Atopic Dermatitis Based on Previous Medication History (encore) (Abstract #P0192. Session: Atopic dermatitis/Eczema)

Effects of Ruxolitinib Cream in Patients with Atopic Dermatitis with Baseline Body Surface Area 10% and Eczema Area and Severity Index Score 16 (encore) (Abstract #P0190. Session: Atopic dermatitis/Eczema)

Patient-Reported Outcomes of Ruxolitinib Cream for the Treatment of Atopic Dermatitis (encore) (Abstract #P0188. Session: Atopic dermatitis/Eczema)

More information regarding the virtual conference is available on the EADV website: https://www.eadvcongress2021.org/. Following the conference, all e-Posters will be made available online on http://www.eadv.org for EADV members.

About Ruxolitinib Cream

Ruxolitinib cream is a proprietary formulation of Incytes selective JAK1/JAK2 inhibitor ruxolitinib that has been designed for topical application. Ruxolitinib cream is currently in Phase 3 development for the treatment of adolescents and adults with atopic dermatitis (TRuE-AD) and vitiligo (TRuE-V). Incyte has worldwide rights for the development and commercialization of ruxolitinib cream.

About Incyte Dermatology

Incytes science-first approach and expertise in immunology has formed the foundation of the company. In Dermatology, the Companys research and development efforts are focused on leveraging our knowledge of the JAK-STAT pathway to identify and develop topical and oral therapies with the potential to modulate immune pathways driving uncontrolled inflammation and help restore normal immune function.

Currently, Incyte is exploring the potential of JAK inhibition for a number of immune-mediated dermatologic conditions with a high unmet medical need, including atopic dermatitis, vitiligo and hidradenitis suppurativa. To learn more, visit the Dermatology section of Incyte.com.

About Incyte

Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.

Forward-Looking Statements

Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding Incytes TRuE-V clinical program, whether and when ruxolitinib cream might be approved to treat patients with vitiligo or atopic dermatitis (AD), the potential for success of such treatment, and Incytes Dermatology program generally, contain predictions, estimates and other forward-looking statements.

These forward-looking statements are based on the Companys current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; the effects of the COVID-19 pandemic and measures to address the pandemic on the Companys clinical trials, supply chain, other third-party providers and development and discovery operations; determinations made by the U.S. FDA and other regulatory authorities outside of the United States; the efficacy or safety of the Companys products; the acceptance of the Companys products in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; and other risks detailed from time to time in the Companys reports filed with the Securities and Exchange Commission, including its annual report and its quarterly report on Form 10-Q for the quarter ended June 30, 2021. The Company disclaims any intent or obligation to update these forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210913005816/en/

Contacts

Media Catalina Loveman+1 302 498 6171cloveman@incyte.com

Jenifer Antonacci+1 302 498 7036jantonacci@incyte.com

Investors Christine Chiou+1 302 274 4773cchiou@incyte.com

More:
Incyte Announces Ruxolitinib Cream Data Accepted for Presentation at the 2021 European Academy of Dermatology and Venereology (EADV) Virtual Congress...